当前位置: X-MOL 学术Int. J. Cardiol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Fontan-associated nephropathy: Predictors and outcomes.
International Journal of Cardiology ( IF 3.2 ) Pub Date : 2020-01-10 , DOI: 10.1016/j.ijcard.2020.01.014
Jacqueline Nguyen Khuong 1 , Thomas G Wilson 1 , Leeanne E Grigg 2 , Andrew Bullock 3 , David Celermajer 4 , Patrick Disney 5 , Vishva A Wijesekera 6 , Tim Hornung 7 , Diana Zannino 8 , Ajay J Iyengar 9 , Yves d'Udekem 9
Affiliation  

BACKGROUND Nephropathy is a known complication of the Fontan circulation, but its determinants have not been identified and patient outcomes are also still unknown. METHODS The Australia and New Zealand Fontan Registry was used to identify those who underwent Fontan operation before and survived beyond 16-years-old with an intact Fontan circulation. Serum creatinine values were collected for each patient between 16 and 25 years and at recent follow-up. The Modification of Diet in Renal Disease (MDRD) equation was used to calculate eGFR. Patient outcomes were obtained from the Registry. Fontan failure was defined as death, transplantation, plastic bronchitis, protein losing enteropathy, Fontan takedown and NYHA class III-IV. RESULTS Serum creatinine measurements were available for 328 patients. Renal dysfunction was defined as eGFR <90 mL/min/1.72m2. Renal dysfunction was present in 67/328 (20%) and 3/328 (1%) patients had an eGFR <60 mL/min/1.72m2. The 10-year survival and 10-year freedom from death and transplantation were the same, 96% (95% CI: 0.9-1) for those with renal dysfunction, and 89% (0.83-0.95; p = 0.1) and 87% (95% CI: 0.81-0.94; p = 0.05) for patients without dysfunction. The 10-year freedom from failure were also similar, 83% (95% CI: 0.70-0.97) for those without renal dysfunction vs 80% (95% CI: 0.74-0.89; p = 0.84). There was no change in mean eGFR for the renal dysfunction group over a mean of 8 ± 5.5 years. CONCLUSION By the time they reach adulthood, 20% of patients with a Fontan circulation have renal dysfunction by eGFR calculation. Over the course of one decade, Fontan-associated nephropathy appears well tolerated.

中文翻译:

方丹相关性肾病:预测因素和结果。

背景技术肾病是Fontan循环的已知并发症,但尚未确定其决定因素,患者预后也仍然未知。方法使用澳大利亚和新西兰丰坦登记册来识别那些以前曾接受过丰坦手术并在丰坦循环​​完整的情况下存活超过16岁的患者。在最近的随访中收集了每位患者16至25岁之间的血清肌酐值。肾脏疾病饮食的修改(MDRD)方程用于计算eGFR。从登记处获得患者结果。丰坦衰竭的定义为死亡,移植,可塑性支气管炎,蛋白质丢失性肠病,丰坦脱钩和NYHA III-IV级。结果328例患者可进行血清肌酐测量。肾功能不全定义为eGFR < 90 mL /分钟/1.72m2。肾功能不全存在于67/328(20%)和3/328(1%)患者的eGFR <60 mL / min / 1.72m2。肾功能不全者的10年生存率和10年死亡和移植自由率相同,肾功能不全者为96%(95%CI:0.9-1),89%(0.83-0.95; p = 0.1)和87%没有功能障碍的患者(95%CI:0.81-0.94; p = 0.05)。10年无故障率也相似,无肾功能不全者为83%(95%CI:0.70-0.97),而80%(95%CI:0.74-0.89; p = 0.84)。肾功能不全组的平均eGFR在平均8±5.5年内没有变化。结论到成年时,通过eGFR计算,有20%的Fontan循环患者患有肾功能不全。在十年的过程中,与Fontan相关的肾病似乎耐受良好。肾功能不全存在于67/328(20%)和3/328(1%)患者的eGFR <60 mL / min / 1.72m2。肾功能不全者的10年生存率和10年死亡和移植自由率相同,肾功能不全者为96%(95%CI:0.9-1),89%(0.83-0.95; p = 0.1)和87%没有功能障碍的患者(95%CI:0.81-0.94; p = 0.05)。10年无故障率也相似,无肾功能不全者为83%(95%CI:0.70-0.97),而80%(95%CI:0.74-0.89; p = 0.84)。肾功能不全组的平均eGFR在平均8±5.5年内没有变化。结论到成年时,通过eGFR计算,有20%的Fontan循环患者患有肾功能不全。在十年的过程中,与Fontan相关的肾病似乎耐受良好。肾功能不全存在于67/328(20%)和3/328(1%)患者的eGFR <60 mL / min / 1.72m2。肾功能不全者的10年生存率和10年死亡和移植自由率相同,肾功能不全者为96%(95%CI:0.9-1),89%(0.83-0.95; p = 0.1)和87%没有功能障碍的患者(95%CI:0.81-0.94; p = 0.05)。10年无故障率也相似,无肾功能不全者为83%(95%CI:0.70-0.97),而80%(95%CI:0.74-0.89; p = 0.84)。肾功能不全组的平均eGFR在平均8±5.5年内没有变化。结论到成年时,通过eGFR计算,有20%的Fontan循环患者患有肾功能不全。在十年的过程中,与Fontan相关的肾病似乎耐受良好。
更新日期:2020-01-11
down
wechat
bug